Wei Kang walked into the office early in the morning, Wenren Long came over excitedly to report.
"Boss, the Phase I trial reports for Severing Love Spirit are out."
"Toxicological studies have found that it has no serious adverse effects on normal people and HIV patients, and can effectively inhibit the binding of the virus to the CCR5 receptor. The effect is as outstanding as ever, just like me."
He raised his head, his voice high-pitched and impassioned, like a rooster crowing.
"Through the treatment of 40 HIV-positive adult patients, these patients took the drug alone at different doses for 10 days, and the HIV virus in their bodies was greatly reduced. The reduction was most significant in the patients who used the maximum dose, reaching more than 95%."
"The fact that patients did not experience a rebound in the short term after stopping the medication is sufficient proof of the drug's efficacy."
"Patients who had been treated previously and those who did not respond to Retrovirus therapy also had the same response."
"Mild adverse reactions have been observed in about 5% of patients, including diarrhea, fever, and loss of appetite, but these symptoms usually disappear after 1-3 days of continued treatment."
"Because the patients have been taking the medication for a relatively short period of time, the long-term treatment effect needs to be studied in Phase III Clinical Trial."
"In summary, this drug has very high activity, low cytotoxicity, excellent pharmacokinetics, no potential drug-drug interactions, and extremely high safety, making it a promising treatment for AIDS infection."
Wei Kang nodded in satisfaction. "Thank you for your hard work. In that case, the Phase III Clinical Trial can begin immediately."
"Many pharmaceutical companies are developing similar drugs now, and several are already in the clinical stage. You should hurry up."
Wenren Long smiled and said confidently, "Currently, the only CCR5 Antagonist drug that has truly become a first-line drug Maraviroc, which was launched more than ten years ago. However, this drug has significant side effects and many restrictions on its use, so it has not become truly widespread."
"Don't worry, boss, our medicine is more effective, has fewer side effects, and can eliminate the HIV virus more thoroughly."
" In the Phase III Clinical Trial, we will choose Maraviroc as the control group. The contrast will be stark, and it will completely outperform it."
"Alright, then it's up to you."
That afternoon, Sanqing Group announced the successful development of a specific drug for HIV.
They even included the name "Severing Love Spirit".
Soon, the entire internet was in an uproar.
"Three Purities has successfully developed a new drug that is highly effective in eliminating the HIV virus!"
"When HIV is no longer a terminal illness, will patients still have unspeakable secrets?"
"Humanity has finally conquered the beast that is AIDS!"
"The appearance of 'Severing Love Spirit' has finally allowed those innocent people to raise their heads!"
News articles appeared online at lightning speed, and related topics surged to the top of the trending search list within just one hour.
They've completely suppressed all those TV dramas and movies featuring young, attractive actors that spent a lot of money on promotion.
Netizens were outraged when they saw this news.
"Holy crap, the Three Purities have finally made their move on HIV?"
"That's great, I don't have to worry about getting infected anymore."
"Upstairs, you told me your story. Why are you worried about getting infected? If an ordinary person hasn't done anything wrong, the probability of getting infected is extremely low."
"I still remember the trending topic before, a young man passed the civil service exam and passed the exam. It should have been a happy occasion, but then he was diagnosed with HIV during the physical examination. Ugh, I hope people like him won't be affected in the future."
"People like this are not careful and deserve to be found out. Those who are infected through blood donation are the ones who are pitiful. I have read reports about AIDS Village. It is so pitiful. The whole village, mostly the elderly, weak and disabled, have been infected. It is a tragedy."
"With the Three Purities medicine, the AIDS Village problem should be over."
"The most pitiful are babies born with HIV. They come into this world without doing anything wrong and are then hit hard. It's so cruel."
"These people are all pitiful. The case of the editor who was sentenced for having a baby was an example of how parents who were both HIV-positive made efforts to give birth to a healthy baby. If this drug were available, they probably wouldn't have done that."
"Apart from those who messed around, the other infected people are all innocent and pitiful, and they desperately need such a special drug to save their lives."
"What right do people who get sick from messing around have to take this medicine? They brought it on themselves. Now that they can be cured, they will definitely mess around even more in the future. It will be really impossible to guard against them."
"The hospital has to protect the privacy of this kind of person and can't tell their relatives. I have a friend whose husband was infected. They kept it from her during the premarital checkup, and he got infected after marriage. It's so tragic."
"In the future, AIDS will be a common infectious disease, just like hepatitis A Hepatitis B. Then patients won't need to hide it anymore. It seems like a good thing."
"I hope so. Everyone should be careful. Maybe soon someone around you will come forward and say that they are HIV carriers. We used to keep it a secret from them, but now that it's treatable, let's see how they can keep it a secret then."
"I hope so. Anyway, I'll still stay far away from people like that in the future."
Judging from the reactions of netizens, it is clear that AIDS has become a fearsome disease thanks to the media's relentless propaganda over the past decade.
The main reason is the high degree of concealment and high infectivity of the HIV virus. The incubation period of HIV in the human body can be as long as 8 years, during which time one can live for many years without any symptoms.
Some people, once they have no worries about life, like to seek thrills and become more open about certain things, which makes them more likely to fall into traps unintentionally.
Some people are infected by those who seek revenge against society. After contracting the disease, these people are prone to developing a vengeful mentality due to the pessimism brought about by the terminal illness. Why should they be the ones who are sick while others are not?
If someone passes it on to him, he'll pass it on to others; if everyone's going to be unlucky, they'll all be unlucky together.
With such intentions, spreading rumors everywhere is truly impossible to guard against.
This leads to a greater fear of this disease compared to other terminal illnesses.
After all, most terminal illnesses are not contagious, so they don't need to worry.
This is why AIDS has become a public health issue, and why one million infected people across the country can receive free drug treatment at the CDC.
While netizens were discussing it enthusiastically, the news quickly spread overseas.
Three Purities's every move has always been closely watched by its many competitors.
Generally speaking, when pharmaceutical companies are investing in hot sectors and new drugs, they need to keep abreast of the latest industry news in order to have a more intuitive understanding of the competitive landscape of a particular product.
Especially in the highly competitive pipeline sector, pharmaceutical companies are all making efforts to launch their own new drugs targeting the same target.
This means that if similar drugs clash with each other, and a competitor develops one first and goes through clinical trials before you, they may completely seize the initiative.
Especially for groundbreaking first-in-class drugs, the first one developed often gets a fast track to approval and market launch, while later developers don't get that treatment.
The first drug can often be launched quickly within a few months, but the second drug has to go through the conventional channels and take two or three years longer to be launched.
Not only will they fall behind and lose the opportunity to seize the market, but sometimes, seeing that the other party has too much of an advantage, pharmaceutical companies may even abandon the project and terminate the clinical trial. In this way, all the previous R&D investment will be completely wasted.
The field of anti-AIDS drugs is undoubtedly one of the most competitive.
The target of CCR5 Antagonist is also quite popular.
Therefore, the first to get restless were the companies developing CCR5 Antagonist.
This is especially true for pharmaceutical companies that have already achieved results and entered the clinical trial stage.
The Eagle Country, Merck headquarters.
An emergency board meeting is underway.
All the directors felt utterly helpless when they saw the news.
After a 15-year hiatus, Three Purities has developed CCR5 Antagonist?
That's not a big deal, but it clashes with one of the company's new anti-HIV drugs.
Merck's new drug, a small molecule antagonist targeting CCR5, has entered Phase 2 clinical trials.
The data in all aspects are excellent, and after a series of structural modifications, adverse reactions have been greatly reduced.
The company has always been optimistic about it and wants to make a remarkable comeback in the field of anti-AIDS drugs with this drug.
In the global AIDS drug market, Gilead, GSK (GSK), Bristol Myers Squibb (BMS), Merck, and Johnson & Johnson & Johnson are the main companies. Although Gilead is the absolute leader, it is currently engaged in fierce competition with GSK, which is in second place.
However, Merck is able to get a share of the more than $30 billion anti-AIDS drugs market because it has several drugs with good efficacy.
It's just that its presence in the global market is very low.
CRR5 is indeed a popular target with many new drugs in development, but none of them have made it to Phase III.
It's already quite an achievement that their drug has entered Phase 2 clinical trials.
However, this Three Purities is simply a freak.
Suddenly, a new anti-AIDS drug was developed and entered Phase III.
This is utterly unethical, and as a result, their new drug will clash with the Three Purities's new drug.
Upon seeing the Phase II data disclosed by Three Purities, the board members fell silent.
Even a blind person could see the efficacy of this new drug; it absolutely blows away their other new drugs targeting the same target.
Indeed, if they could develop a new drug comparable to Three Purities, they wouldn't have been so repeatedly defeated by Gilead.
Merck's chief pharmaceutical expert sighed, "I'm sorry, the data for this drug is perfect. It seems we've lost this time."
"I suggest we abandon this CCR5 Antagonist. We have several new anti-HIV drugs in development targeting different targets. We can put our resources into other projects, which may be more promising," a director suggested.
"However, this means that with Gilead ahead and Three Purities constantly catching up from behind, we are caught in the middle, which is very difficult, especially since we are relatively far behind. We may have to watch helplessly as Three Purities takes away our market share."
"We will eventually lose the market for anti-AIDS drugs completely."
"For this kind of effective drug, the FDA in various countries will definitely simplify the approval process and bring it to market as soon as possible. We don't have much time left."
"They've already reached Phase 3 clinical trials, while we're only at Phase 2. How are we supposed to catch up?"
"Perhaps the company should consider changing its research and development direction."
The board members started discussing it amongst themselves.
Ultimately, they decided to abandon the Phase 2 clinical trial of this drug.
Companies like GSK, Gilead, BMS, and Johnson & Johnson are also paying attention to Sanqing new drug.
These top pharmaceutical companies, which all hold significant territories in the anti-AIDS drug market, were all quite shocked by this.
It seems that another formidable player is about to join this crowded market, stirring up the market landscape.
They instantly sensed a profound crisis.
As one of the undisputed champions of anti-AIDS drugs, GSK says this little brother is pretty fierce.
It might not be able to withstand a knife stabbing in from behind.
HIV drug treatment has evolved over the decades, from the monotherapy 1.0 era to the Cocktail Therapy 2.0 era, and then to the future complete cure 3.0 era, fully demonstrating the vigorous development of human technology.
From the earliest discovery of HIV to the FDA's approval of the first treatment, people didn't have to wait long.
In the 1980s, GSK developed the first weapon in the fight against HIV and brought it to market through rapid review, giving HIV-infected people hope for survival for the first time.
Thus, HIV drug treatment officially entered its 1.0 era.
However, the first-generation Retrovirus drugs were obviously outdated and could not keep up with the changes in HIV, so patients would still die quickly at that time.
Since the 1990s, various new anti-HIV mechanisms have gradually emerged, and a series of new HIV drugs, such as Protease Inhibitor and Fusion Inhibitor, have begun to increase rapidly.
HIV treatment has suddenly escaped the predicament of having very limited options for single-drug therapy.
Against this backdrop, Professor He's team of Chinese scientists proposed a novel combination drug administration strategy—Highly Active Retrovirus Therapy (HAART), also known as Cocktail Therapy.
Because it can both prevent the HIV virus from multiplying and prevent the development of drug-resistant viruses in the body, Cocktail Therapy quickly became the standard treatment for HIV.
This was a revolutionary breakthrough. GSK seized the opportunity and quickly followed suit, becoming the first to launch a triple combination therapy, which reduced the disease mortality rate by more than half and made it the undisputed leader in HIV treatment drug.
In addition to GSK, Gilead, Merck, Johnson & Johnson, and other pharmaceutical giants, a number of others have also quickly joined the effort to develop HIV Cocktail Therapy.
Thus, HIV drug administration was reduced from multiple times a day to once a day, and then to once every two weeks, greatly improving treatment adherence.
More importantly, HIV treatment has also undergone a perfect transformation from the period of confusion in the 1.0 era to the 2.0 era.
HIV is gradually becoming a manageable chronic disease.
Data shows that during this period, the number of HIV-related deaths worldwide also dropped from 1.9 million to nearly 1 million. In other words, the ever-evolving HIV drugs saved millions of lives.
In this process, GSK was a pioneer in HIV therapy, possessing the first HIV treatment drug and the first Cocktail Therapy, which established its absolute dominance in the early HIV drug market. In the HIV field, which was almost exclusively entered by multinational pharmaceutical giants, GSK steadily suppressed its old rivals one by one.
However, GSK did not remain at the top for long. In 2006, with the launch of Atripla by Gilead, its good clinical efficacy and low cost led to a series of defeats for GSK in just a few years.
From then on, Gilead officially replaced GSK as the global leader in the HIV market.
With the emergence of Biktarvy in 2018, it swept the globe and achieved sales of $7.3 billion in its second year on the market, becoming the king of HIV drugs.
Biktarvy helped Gilead once hold more than 60% of the global HIV drug market share, and it still maintains a high growth rate of 8%. As of now, no drug has been able to shake its position.
In contrast, GSK's situation in recent years has been rather unfortunate. Although it still has several blockbuster drugs, its growth is far from optimistic, and its sales fell by 30% last year.
As a long-established giant, GSK did not choose to sit idly by and wait for its demise. Instead, it quickly developed a new long-acting injectable drug that can be administered once a month.
The script seems so familiar: GSK has mastered revolutionary technology and taken the lead, but this time GSK has become the challenger, and Gilead has become the responder who counters each move.
Both sides were practically fighting with their brains completely out of control.
Just then, Three Purities's new HIV drug arrived, albeit late, and its future looks promising.
This will usher in a new era for anti-AIDS drugs, making them curable.
Although it still requires long-term medication like a chronic disease, it can indeed be cured and the virus can be completely eliminated from the body.
The 1.0 and 2.0 eras of HIV treatment have become history, and the curtain has been raised on the 3.0 era.
After a long battle lasting decades, HIV has transformed from a super Cancer into a manageable chronic disease.
This is scientific progress and also a stroke of luck for humankind.